With this approval, Bharat Biotech achieved another significant milestone in innovating and manufacturing vaccines at global quality standards and moving forward in the ongoing fight against the Covid-19 pandemic, read Bharat Biotech statement.
Indigenous coronavirus disease (Covid-19) vaccine Covaxin manufactured by Bharat Biotech has received Good Manufacturing Practices (GMP) compliance certificate from Hungary.
“Another milestone in our account as COVAXIN receives GMP certificate from Hungary. This marks the 1st EUDRAGDMP compliance certificate received by Bharat Biotech from European regulatories,” Bharat Biotech tweet said.
Another milestone in our account as COVAXIN® receives GMP certificate from Hungary. This marks the 1st EUDRAGDMP compliance certificate received by Bharat Biotech from European regulatories. pic.twitter.com/0x8BLF2jWR
— BharatBiotech (@BharatBiotech)The approval received is from the National Institute of Pharmacy and Nutrition, Hungary certifying the GMP for the manufacture of Covaxin, a note posted on twitter said.
The certificate of GMP is now listed on the EudraGMDP database which is the collection of records of the European Community of manufacturing authorisations and certificates of good manufacturing practice, Bharat Biotech said.
The certificate has now been listed with other certificates on the EudraGMDP database which is the database of the European Community of manufacturing authorisations and certificates of the good manufacturing practice.
Bharat biotech has been submitting documentations for Emergency Use Authorisation (EUA) in several countries worldwide.
"With this approval Bharat Biotech has achieved another significant milestone in innovating and manufacturing vaccines at Global quality standards and moving forward in the ongoing fight against the COVID-19 pandemic," the company said in a note on Twitter.
The recognition compliments the firm's commitment of driving world class innovation and being a frontrunner in the research and development of vaccines, it added.
Meanwhile, Bharat Biotech's Covid-19 vaccine Covaxin has shown less reduction in 'neutralizing activity' while comparing with Delta and Delta AY.1 (Delta plus) variants in those who are fully vaccinated with the vaccine according to a study by the Indian Council of Medical Research-National Institute of Virology (NIV).
This means that people vaccinated with Covaxin will be protected against the current variants Delta, Delta AY.1 and B.1.617.3.
NOTE: Asianet News humbly requests everyone to wear masks, sanitize, maintain social distancing and get vaccinated as soon as eligible. Together we can and will break the chain #ANCares #IndiaFightsCorona
Read Exclusive COVID-19 Coronavirus News updates, at MyNation.